Enhancement of systemic tumor immunity for squamous cell carcinoma cells by an oncolytic herpes simplex virus. 2013

N Meshii, and G Takahashi, and S Okunaga, and M Hamada, and S Iwai, and A Takasu, and Y Ogawa, and Y Yura
Department of Oral and Maxillofacial Surgery, Osaka University Graduate School of Dentistry, Osaka, Japan.

RH2 is a neurovirulent γ134.5 gene-deficient herpes simplex virus type 1 (HSV-1) with a lytic ability in human squamous cell carcinoma (SCC) cells; it is related to spontaneously occurring HSV-1 mutant HF10. The effect of RH2 on SCC was examined using a syngeneic C3H mouse model. After infection of mouse SCCVII cells with RH2, cell viability was decreased at first, but recovered by prolonged culture, indicating the limited replication of RH2. The antitumor ability of RH2 was examined using a bilateral SCCVII tumor model. The growth of the RH2-injected tumors was suppressed compared with that of phosphate-buffered saline-injected tumors. Moreover, the growth of contralateral tumor of RH2-treated mice was also suppressed significantly. The splenocytes of C3H mice treated with RH2 lysed more SCCVII cells than NFSaY83 cells and YAC-1 cells. The cytotoxicity of the splenocytes on SCCVII cells was significantly greater than that of splenocytes from tumor-bearing mice. Removal of CD8(+) T cells from splenocytes decreased their cell killing activity remarkably. The antitumor effect of RH2 on SCCVII xenografts in nude mice was not demonstrated. These results indicate that RH2 exhibited a suppressive effect on mouse SCC, even if the replication of RH2 was limited. This is ascribed to the ability of RH2 to enhance existing tumor-specific cytotoxic T lymphocyte activity.

UI MeSH Term Description Entries
D008212 Lymphocyte Depletion Immunosuppression by reduction of circulating lymphocytes or by T-cell depletion of bone marrow. The former may be accomplished in vivo by thoracic duct drainage or administration of antilymphocyte serum. The latter is performed ex vivo on bone marrow before its transplantation. Depletion, Lymphocyte
D008819 Mice, Nude Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses. Athymic Mice,Mice, Athymic,Nude Mice,Mouse, Athymic,Mouse, Nude,Athymic Mouse,Nude Mouse
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D002294 Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed) Carcinoma, Epidermoid,Carcinoma, Planocellular,Carcinoma, Squamous,Squamous Cell Carcinoma,Carcinomas, Epidermoid,Carcinomas, Planocellular,Carcinomas, Squamous,Carcinomas, Squamous Cell,Epidermoid Carcinoma,Epidermoid Carcinomas,Planocellular Carcinoma,Planocellular Carcinomas,Squamous Carcinoma,Squamous Carcinomas,Squamous Cell Carcinomas
D003602 Cytotoxicity, Immunologic The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement. Tumoricidal Activity, Immunologic,Immunologic Cytotoxicity,Immunologic Tumoricidal Activities,Immunologic Tumoricidal Activity,Tumoricidal Activities, Immunologic
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D005260 Female Females
D005822 Genetic Vectors DNA molecules capable of autonomous replication within a host cell and into which other DNA sequences can be inserted and thus amplified. Many are derived from PLASMIDS; BACTERIOPHAGES; or VIRUSES. They are used for transporting foreign genes into recipient cells. Genetic vectors possess a functional replicator site and contain GENETIC MARKERS to facilitate their selective recognition. Cloning Vectors,Shuttle Vectors,Vectors, Genetic,Cloning Vector,Genetic Vector,Shuttle Vector,Vector, Cloning,Vector, Genetic,Vector, Shuttle,Vectors, Cloning,Vectors, Shuttle
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

N Meshii, and G Takahashi, and S Okunaga, and M Hamada, and S Iwai, and A Takasu, and Y Ogawa, and Y Yura
October 2015, Viruses,
N Meshii, and G Takahashi, and S Okunaga, and M Hamada, and S Iwai, and A Takasu, and Y Ogawa, and Y Yura
April 2016, Cancer gene therapy,
N Meshii, and G Takahashi, and S Okunaga, and M Hamada, and S Iwai, and A Takasu, and Y Ogawa, and Y Yura
January 2008, Anticancer research,
N Meshii, and G Takahashi, and S Okunaga, and M Hamada, and S Iwai, and A Takasu, and Y Ogawa, and Y Yura
July 2001, Journal of the American College of Surgeons,
N Meshii, and G Takahashi, and S Okunaga, and M Hamada, and S Iwai, and A Takasu, and Y Ogawa, and Y Yura
January 2018, Cancers,
N Meshii, and G Takahashi, and S Okunaga, and M Hamada, and S Iwai, and A Takasu, and Y Ogawa, and Y Yura
June 2011, Virology journal,
N Meshii, and G Takahashi, and S Okunaga, and M Hamada, and S Iwai, and A Takasu, and Y Ogawa, and Y Yura
January 2003, International review of neurobiology,
N Meshii, and G Takahashi, and S Okunaga, and M Hamada, and S Iwai, and A Takasu, and Y Ogawa, and Y Yura
September 2017, Cancer gene therapy,
N Meshii, and G Takahashi, and S Okunaga, and M Hamada, and S Iwai, and A Takasu, and Y Ogawa, and Y Yura
March 2009, Cancer gene therapy,
N Meshii, and G Takahashi, and S Okunaga, and M Hamada, and S Iwai, and A Takasu, and Y Ogawa, and Y Yura
May 2004, Molecular therapy : the journal of the American Society of Gene Therapy,
Copied contents to your clipboard!